NZ787393A - New methylquinazolinone derivatives - Google Patents

New methylquinazolinone derivatives

Info

Publication number
NZ787393A
NZ787393A NZ787393A NZ78739320A NZ787393A NZ 787393 A NZ787393 A NZ 787393A NZ 787393 A NZ787393 A NZ 787393A NZ 78739320 A NZ78739320 A NZ 78739320A NZ 787393 A NZ787393 A NZ 787393A
Authority
NZ
New Zealand
Prior art keywords
compound
formula
compound according
cancer
prophylaxis
Prior art date
Application number
NZ787393A
Other versions
NZ787393B2 (en
Inventor
David Stephen Hewings
Daniela Krummenacher
Piergiorgio Francesco Tommaso Pettazzoni
Juergen Wichmann
Cosimo Dolente
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NZ787393A publication Critical patent/NZ787393A/en
Publication of NZ787393B2 publication Critical patent/NZ787393B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Harvester Elements (AREA)
  • Combines (AREA)

Abstract

The invention provides a novel compound having the general formula (I), or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament in the treatment or prophylaxis of cancer and is a BRAF inhibitor..

Claims (14)

Claims
1.
2. The nd of formula (I) or a pharmaceutically acceptable salt thereof. 5 2. A nd according to claim 1, wherein the compound is the compound of formula (I).
3. A compound according to claim 1 or 2, wherein the compound is the compound of formula (Ia).
4. A compound according to claim 1, wherein the compound is a pharmaceutically acceptable 10 salt of the compound of formula (Ia) (Ia).
5. A compound according to claim 1 or 2, n the compound is the compound of formula (Ib).
6. A process for the preparation of a compound according to any one of claims 1 to 5, comprising the reaction of a compound of formula (B1) 5 with a compound of formula (B2) in the presence of a base.
7. A compound according to any one of claims 1 to 5 for use as therapeutically active 10 substance.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 and a eutically inert carrier.
9. A compound according to any one of claims 1 to 5 for use in the treatment or prophylaxis of cancer. 15
10. A nd according to any one of claims 1 to 5 for use in the treatment or prophylaxis of thyroid cancer, colorectal , brain cancer, melanoma or NSCLC.
11. The use of a compound according to any one of claims 1 to 5 for the ation of a medicament for the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
12. The compound according to any one of claims 1 to 5, 7, 9 and 10, substantially as herein 5 described with reference to any example f and with or without reference to the accompanying drawings.
13. The process according to claim 6, substantially as herein described with reference to any example thereof and with or t reference to the accompanying gs.
14. The pharmaceutical composition of claim 8, substantially as herein described with reference 10 to any example thereof and with or without reference to the accompanying drawings. W0 2021/] 16055
NZ787393A 2020-12-08 New methylquinazolinone derivatives NZ787393B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (2)

Publication Number Publication Date
NZ787393A true NZ787393A (en) 2025-07-25
NZ787393B2 NZ787393B2 (en) 2025-10-29

Family

ID=

Also Published As

Publication number Publication date
CN114787156B (en) 2024-07-26
EP4073065B1 (en) 2025-02-19
BR112022011123A2 (en) 2022-08-23
LT4073065T (en) 2025-04-25
MA58087B1 (en) 2025-04-30
CN118791472A (en) 2024-10-18
PH12022551119A1 (en) 2023-08-23
TW202136245A (en) 2021-10-01
JP7108146B2 (en) 2022-07-27
ZA202204675B (en) 2022-12-21
HRP20250418T1 (en) 2025-06-06
AU2020403443A1 (en) 2022-05-12
SI4073065T1 (en) 2025-06-30
US20240174621A1 (en) 2024-05-30
KR102836833B1 (en) 2025-07-22
KR20220110554A (en) 2022-08-08
PE20221778A1 (en) 2022-11-16
EP4483882A3 (en) 2025-03-05
ES3023264T3 (en) 2025-05-30
IL316473A (en) 2024-12-01
PT4073065T (en) 2025-04-15
HUE071148T2 (en) 2025-08-28
IL292161A (en) 2022-06-01
RS66721B1 (en) 2025-05-30
MX2022006783A (en) 2022-07-11
CL2022001529A1 (en) 2023-02-10
PL4073065T3 (en) 2025-05-19
US20220298119A1 (en) 2022-09-22
IL292161B2 (en) 2025-04-01
EP4483882A2 (en) 2025-01-01
FI4073065T3 (en) 2025-04-16
AR122351A1 (en) 2022-09-07
TWI877268B (en) 2025-03-21
WO2021116055A1 (en) 2021-06-17
CA3162883A1 (en) 2021-06-17
ZA202206923B (en) 2024-10-30
CR20220251A (en) 2022-07-11
US12116349B2 (en) 2024-10-15
CN114787156A (en) 2022-07-22
IL292161B1 (en) 2024-12-01
DK4073065T3 (en) 2025-04-22
TW202504895A (en) 2025-02-01
EP4073065A1 (en) 2022-10-19
TWI908405B (en) 2025-12-11
JP7802514B2 (en) 2026-01-20
JP2022531609A (en) 2022-07-07
AU2020403443B2 (en) 2023-02-23
UA128299C2 (en) 2024-05-29
CO2022008968A2 (en) 2022-07-19
JP2022124458A (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL292161B1 (en) New methylquinazolinone derivatives
ZA202308118B (en) Cdk inhibitor
MX2025003821A (en) Compounds with anti-kras mutant tumor activity
CO2024003923A2 (en) Use of an ezh2 inhibitor in the preparation of drugs for the treatment of t-cell lymphoma
WO2023030685A8 (en) Novel ras inhibitors
CR20230404A (en) Quinazoline compound for inducing degradation of g12d-mutation kras protein
JOP20240136A1 (en) Pharmaceutical formulation containing the compound quinazoline
EP4613335A3 (en) Camptothecin compound, preparation method therefor, and application thereof
WO2023078333A8 (en) Substituted phenylpropionic acid derivative and use thereof
SA523450286B1 (en) 4-aminoquinazoline compound
PH12019501685A1 (en) Quinazone compound
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12022553024A1 (en) Inhibitors of nek7 kinase
PH12023552774A1 (en) Nek7 inhibitors
MX2021010106A (en) Inhibitors of integrated stress response pathway.
MX2024006074A (en) SELECTIVE PARP1 INHIBITOR AND ITS APPLICATION.
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
MX2023012840A (en) Phthalazinone derivatives as nlrp3 inflammasome inhibitors.
MX2023003576A (en) Compound as akt kinase inhibitor.
PE20221768A1 (en) EGFR INHIBITORS
ZA202210629B (en) Pharmaceutical composition comprising benzimidazole derivative compound
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2023000577A (en) Pyrazolopyrimidine compound used as atr kinase inhibitor.
SA521422467B1 (en) Haloallylamine compounds and application thereof
ZA202403327B (en) Halogenated phenylarsine oxide compound and application thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2026 BY ANAQUA SERVICES

Effective date: 20251120